Pfizer’s second-quarter earnings plunged 79 percent from last year, when the world’s second-largest drugmaker booked a $10 billion-plus gain from a business spinoff.
The New York company said Tuesday it earned $2.91 billion, or 45 cents per share, down from $14.1 billion, or $1.98 per share, last year. Adjusted earnings totaled 58 cents per share, a penny more than analysts expected.
Recommended Stories
Print subscriber? Click here to login/register your account
Digital subscriber? Click here to login/register your account.